The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Open accessAbstract
BACKGROUND: We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains unresolved. METHODS: We conducted a three-group, open-label, randomized, controlled trial in South Africa involving 642 ambulatory patients, all with tuberculosis (confirmed by a positive sputum smear for acid-fast bacilli), human immunodeficiency virus infection, and a CD4+ T-cell count of less than 500 per cubic millimeter. Findings in the earlier-ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 214 patients) and later-ART group (ART initiated during the first 4 weeks of the continuation phase of tuberculosis treatment, 215 patients) are presented here. RESULTS: At baseline, the median CD4+ T-cell count was 150 per cubic millimeter, and the median viral load was 161,000 copies per milliliter, with no significant differences between the two groups. The incidence rate of the acquired immunodeficiency syndrome (AIDS) or death was 6.9 cases per 100 person-years in the earlier-ART group (18 cases) as compared with 7.8 per 100 person-years in the later-ART group (19 cases) (incidence-rate ratio, 0.89; 95% confidence interval [CI], 0.44 to 1.79; P=0.73). However, among patients with CD4+ T-cell counts of less than 50 per cubic millimeter, the incidence rates of AIDS or death were 8.5 and 26.3 cases per 100 person-years, respectively (incidence-rate ratio, 0.32; 95% CI, 0.07 to 1.13; P=0.06). The incidence rates of the immune reconstitution inflammatory syndrome (IRIS) were 20.1 and 7.7 cases per 100 person-years, respectively (incidence-rate ratio, 2.62; 95% CI, 1.48 to 4.82; P<0.001). Adverse events requiring a switching of antiretroviral drugs occurred in 10 patients in the earlier-ART group and 1 patient in the later-ART group (P=0.006). CONCLUSIONS: Early initiation of ART in patients with CD4+ T-cell counts of less than 50 per cubic millimeter increased AIDS-free survival. Deferral of the initiation of ART to the first 4 weeks of the continuation phase of tuberculosis therapy in those with higher CD4+ T-cell counts reduced the risks of IRIS and other adverse events related to ART without increasing the risk of AIDS or death. (Funded by the U.S. President's Emergency Plan for AIDS Relief and others; SAPIT ClinicalTrials.gov number, NCT00398996.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905848 · Cited by 666
Self-citationEarlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013911 · Cited by 612
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
Self-citationTreatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Dean, G. L., Edwards, S. G., Ives, N. J., Matthews, G., Fox, E. F., Navaratne, L., Fisher, M., Taylor, G. P., Miller, R., Taylor, C. B., et al. (2002) · AIDS · doi:10.1097/00002030-200201040-00010 · Cited by 354
Lawn, S. D., Myer, L., Bekker, L.-G., & Wood, R. (2007) · AIDS · doi:10.1097/qad.0b013e328011efac · Cited by 343
Pulmonary Tuberculosis in AIDS Patients
Fishman, J. E., Lavi, E. S., Narita, M., et al. (2000) · American Journal of Roentgenology · doi:10.2214/ajr.174.1.1740043 · Cited by 120
Paradoxical Reactions in HIV and Pulmonary TB
Chien, J. W., & Johnson, J. L. (1998) · CHEST Journal · doi:10.1378/chest.114.3.933 · Cited by 102
Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs
Marks, D. J., Dheda, K. U. J., Dawson, R., Ainslie, G., & Miller, R. F. (2009) · International Journal of STD & AIDS · doi:10.1258/ijsa.2008.008361 · Cited by 85
Cohen, K., Grant, A. D., Dandara, C., McIlleron, H., Pemba, L., Fielding, K., Charalombous, S., Churchyard, G., Smith, P. J., & Maartens, G. (2009) · PubMed · Cited by 83
Cohen, K., Grant, A. D., Dandara, C., McIlleron, H., Pemba, L., Fielding, K., Charalombous, S., Churchyard, G., Smith, P. J., & Maartens, G. (2008) · Antiviral Therapy · doi:10.1177/135965350901400502 · Cited by 73
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Zumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Self-citationEarlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013911 · Cited by 612
Health in South Africa: changes and challenges since 2009
Mayosi, B. M., Lawn, J. E., van Niekerk, A., Bradshaw, D., Abdool Karim, S. S., & Coovadia, H. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61814-5 · Cited by 555
t-tests, non-parametric tests, and large studies—a paradox of statistical practice?
Fagerland, M. W. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-78 · Cited by 547
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
Self-citationTiming of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Scaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Marais, B. J., Lönnroth, K., Lawn, S. D., Migliori, G. B., Mwaba, P., Glaziou, P., Bates, M., Colagiuri, R., Zijenah, L., Swaminathan, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70015-x · Cited by 314
Lange, C., Abubakar, I., Alffenaar, J.-W. C., Bothamley, G., Caminero, J. A., Carvalho, A. C. C., Chang, K.-C., Codecasa, L., Correia, A., Crudu, V., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00188313 · Cited by 310
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Dheda, K., Gumbo, T., Gandhi, N. R., Murray, M., Theron, G., Udwadia, Z., Migliori, G. B., & Warren, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70031-1 · Cited by 303
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none
Barber, D. L., Andrade, B. B., Sereti, I., & Sher, A. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2712 · Cited by 169
Louwagie, G. M., Morojele, N., Siddiqi, K., Mdege, N. D., Tumbo, J., Omole, O., Pitso, L., Bachmann, M. O., & Ayo-Yusuf, O. A. (2020) · Translational Behavioral Medicine · doi:10.1093/tbm/ibz100 · Cited by 17
Metadata
- Authors
- Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., Gengiah, T., Gengiah, S., Naidoo, A., Jithoo, N., Nair, G., El-Sadr, W. M., Friedland, G., & Abdool Karim, Q.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-10-20
- Volume
- 365
- Issue
- 16
- Pages
- 1492-1501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117344292
- Cited by
- 487
- References
- 15
- FWCI
- 41.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.